Cyproheptadine is an antagonist for both histamine receptor H1 and the serotonin 2A receptor (HTR2A), suggesting that blocking the serotonin 2A receptor could be specifically helpful for ameliorating symptoms of NAFLD. The gene discussed is HRH1; the disease is metabolic dysfunction-associated steatotic liver disease.